Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Clinical Oncology

• Publication date

  2000-02-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2000.18.4.788PMID 10673520
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute promyelocytic leukemia

  2000cited by this paper
• Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

  1998cited by this paper
• Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.

  1998cited by this paper
• Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RARα Fusion Gene in Patients With Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter “AIDA” Trial

  1998cited by this paper
• Disappearance of PML/RAR alpha acute promyelocytic leukemia-associated transcript during consolidation chemotherapy.

  1998cited by this paper
• Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22).

  1997cited by this paper
• Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461.

  1997cited by this paper
• Defining the "absence" of the CBFbeta/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: a call for definitions.

  1997cited by this paper
• Detection of AML1/ETO fusion transcripts in patients with t(8;21) acute myeloid leukemia after allogeneic bone marrow transplantation or peripheral blood progenitor cell transplantation.

  1997cited by this paper
• Persistence of AML1/ETO fusion mRNA in t(8;21) acute myeloid leukemia (AML) in prolonged remission: is there a consensus?

  1996cited by this paper
• Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor.

  1996cited by this paper
• Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia.

  1996cited by this paper
• Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.

  1996cited by this paper
• Disappearance of AML1 ‐MTG8(ETO) fusion transcript in acute myeloid leukaemia patients with t(8;21) in long‐term remission

  1995cited by this paper
• Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia.

  1995cited by this paper
• Quantitative analysis of AML1/ET0 transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukaemia

  1995cited by this paper
• AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia.

  1995cited by this paper
• AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation.

  1994cited by this paper
• The AML1 gene in the 8;21 and 3;21 translocations in chronic and acute myeloid leukemia.

  1994cited by this paper
• The 8;21 chromosome translocation in acute myeloid leukemia is always detectable by molecular analysis using AML1

  1993cited by this paper
• Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission.

  1993cited by this paper
• An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation.

  1993cited by this paper
• Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction.

  1993cited by this paper
• Acute promyelocytic leukemia.

  1993cited by this paper
• The 8;21 chromosome translocation in acute myeloid leukemia is always detectable by molecular analysis using AML1.

  1993cited by this paper
• Avoiding false positives with PCR

  1989cited by this paper

• Do Surveillance Tests for Relapse Improve Survival After Chemotherapy for Paediatric Acute Leukaemia? A Systematic Review

  2025cites this paper
• Validation of a 12‐color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection

  2023cites this paper
• Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

  2022cites this paper
• Molecular methods for measurable residual disease in acute myeloid leukemia: where are we and where are we going?

  2021cites this paper
• Significance of minimal residual disease monitoring by real‐time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes

  2020cites this paper
• Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy

  2020cites this paper
• Allogeneic hematopoietic stem cell transplantation could improve survival for pure CBF-AML patients with minimal residual disease positive after the second consolidation

  2020cites this paper
• Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia

  2019cites this paper
• Significance of spatial organization of chromosomes in the progression of acute myeloid leukemia

  2017cites this paper
• Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.

  2017cites this paper
• Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.

  2016cites this paper
• Molecular Monitoring of RUNX1-RUNX1T1 Transcript Level in Acute Myeloblastic Leukemias on Treatment

  2016cites this paper
• The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia

  2015cites this paper
• Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors

  2015cites this paper
• Prospective Validation of a New Method of Monitoring Minimal Residual Disease in Childhood Acute Myelogenous Leukemia

  2014cites this paper
• Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1‐RUNX1T1 fusion quantification on genomic DNA

  2014cites this paper
• Monitoring of minimal residual disease in acute myeloid leukemia with t(8;21)(q22;q22)

  2013cites this paper
• transcripts CBFBMYH11+ acute myeloid leukemia based on quantification of fusion New score predicting for prognosis in PML-RARA+, AML1-ETO+, or

  2013cites this paper
• Diagnosis and Treatment of Adult Acute Myeloid Leukemia Other than Acute Promyelocytic Leukemia

  2013cites this paper
• Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.

  2013cites this paper
• Minimal residual disease.

  2012cites this paper
• Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications

  2011cites this paper
• Generation of Monoclonal Antibodies to the AML1-ETO Fusion Protein: Strategies for Overcoming High Homology

  2011cites this paper
• Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?

  2011cites this paper
• Prognostic Factors in Children with Acute Leukemia : Recent Advances

  2010cites this paper
• Molecular Techniques to Detect Disease and Response to Therapy: Minimal Residual Disease

  2010cites this paper
• Nachweis zytogenetischer Aberrationen nach Chemotherapie zur diagnostischen Früherkennung therapieassoziierter hämatologischer Neoplasien

  2010cites this paper
• 10Techniques to Detect Disease and Response to Therapy: Minimal Residual Disease

  2010cites this paper
• Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.

  2009cites this paper
• Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?

  2009cites this paper
• Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation.

  2008cites this paper
• A ≥1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse

  2008cites this paper
• Diagnostic pathways in acute leukemias: a proposal for a multimodal approach

  2007cites this paper
• Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia

  2006cites this paper
• Understanding the Clinical Implications of Minimal Residual Disease in Childhood Leukemia

  2006cites this paper
• Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]

  2006cites this paper
• Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21)

  2005cites this paper
• DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification

  2005cites this paper
• Estudio de la enfermedad mínima residual en el cáncer infantil

  2004cites this paper
• Molecular Disease Eradication is a Prerequisite for Long-term Remission in Patients with t(8;21) Positive Acute Myeloid Leukemia: a Single Center Study

  2004cites this paper
• Molecular Diagnostic Testing in Hematologic Malignancies: A Brief Overview

  2004cites this paper
• Detection of minimal residual disease in acute leukemia.

  2004cites this paper
• Real-Time Quantification of the AML Rearrangements, AML1-ETO and TEL-AML1, in Acute Leukemia

  2004cites this paper
• Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia.

  2004cites this paper
• External quality assurance program for PCR amplification of genomic DNA: an Italian experience.

  2003cites this paper
• Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

  2003cites this paper
• Determination of minimal residual disease in leukaemia patients

  2003cites this paper
• Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT–PCR useful clinically?

  2003cites this paper
• New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.

  2003cites this paper
• Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.

  2003cites this paper
• Recurrence of Acute Myelogenous Leukemia with the SameAML1/ETO Breakpoint as at Diagnosis after Complete Remission Lasting 15 Years: Analysis of Stored Bone Marrow Smears

  2003cites this paper
• Prognostic significance of the AML1-ETO fusion transcript expression in children and young adults with t(8;21) acute myeloid leukemia.

  2003cites this paper
• Prognostic Value of AML1/ETO Fusion Transcripts in Patients with Acute Myelogenous Leukemia

  2003cites this paper
• Monitoring AML1-ETO and CBFΒ-MYH11 transcripts in acute myeloid leukemia

  2003cites this paper
• Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement

  2003cites this paper
• Monitoring minimal residual disease in AML: the right time for real time

  2003cites this paper
• Therapy of Acute Myeloid Leukemia in Adults

  2003cites this paper
• T-immunophenotype is associated with an increased prevalence of thrombosis in children with acute lymphoblastic leukemia. A retrospective study

  2003cites this paper
• Biologie moléculaire et quantification : applications en hématologie

  2003cites this paper
• Follow-up of Minimal Residual Disease in Pediatric Acute Myeloblastic Leukemia Using Metaphase-FISH

  2002cites this paper
• Minimal Residual Disease in Acute Myeloid Leukemia

  2002cites this paper
• Acute myeloid leukemia with t(8;21)/AML1/ETO: a distinct biological and clinical entity.

  2002cites this paper
• Minimal residual disease in acute myeloid leukaemia.

  2002cites this paper
• Assessing minimal residual disease (MRD) in leukemia: a changing definition and concept?

  2002cites this paper
• Amplification of AML1 gene is present in childhood acute lymphoblastic leukemia but not in adult, and is not associated with AML1 gene mutation

  2002cites this paper
• Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

  2002cites this paper
• A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup.

  2002cites this paper
• A white blood cell index as the main prognostic factor in t ( 8 ; 21 ) acute myeloid leukemia ( AML ) : a survey of 161 cases from the French AML Intergroup

  2002cites this paper
• Studies on the core binding factor complex in patients with acute myeloid leukaemia.

  2002cites this paper
• Minimal residual disease evaluation in acute myeloid leukaemia.

  2002cites this paper
• Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts

  2002cites this paper
• Biologie moléculaire et leucémies aiguës

  2002cites this paper
• Genetic profile of acute myeloid leukemia.

  2002cites this paper
• Recent advances in the treatment of AML

  2001cites this paper
• Detection of minimal residual disease.

  2001cites this paper
• Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.

  2001cites this paper
• AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML

  2001cites this paper
• Treatment of acute myeloid leukaemia in younger patients.

  2001cites this paper
• [Residual disease: the hematologist's point of view].

  2001cites this paper
• Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia.

  2001cites this paper
• Role of allogeneic and autologous hematopoietic stem cell transplantation in acute myeloid leukemia.

  2000cites this paper
• Acute myeloid leukemia: therapeutic indications

  2000cites this paper
• The AML1/MTG8 Fusion Transcript in t(8;21) Positive AML and its Implication for the Detection of Minimal Residual Disease

  2000cites this paper
• HEMATOLOGICAL ONCOLOGY

  2000cites this paper
• Avaliação de doença residual mínima pós-transplante de medula óssea

  2000cites this paper